Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade Sarcoma

Table 1

Patient and tumor characteristics.

Age at time of treatment (years)
Median	56
Range	12–85
Patients (𝑛=16)
Male	7 (44%)
Female	9 (56%)
Lesions (𝑛=25)
Peripheral	19 (76%)
Central	6 (24%)
Histology
Leiomyosarcoma	7
Synovial cell	5
Osteosarcoma	4
Liposarcoma	2
NOS	2
Spindle cell	1
Chondrosarcoma	1
Liposarcoma	1
Hemangiopericytoma	1
Embryonal	1
Dose fractionation and BED*
54 Gy, 3 fractions (BED = 151.2 Gy)	13 (52%)
50 Gy, 4 fractions (BED = 112.5 Gy)	9 (36%)
36 Gy, 3 fractions (BED = 79.2 Gy)	2 (8%)
42 Gy, 3 fractions (BED = 100.8 Gy)	1 (4%)

∗Biological equivalent dose is calculated per (1), assuming 𝛼/𝛽 ratio of 10 for tumor (𝑛  = number of fractions, 𝑑 = total dose).